Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multi-season cohort study

(2019) Theodore Lytras et al.   CLINICAL INFECTIOUS DISEASES

Influenza virus polymerase inhibitors in clinical development

(2019) Frederick G. Hayden et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference

(2018) Jennifer L. McKimm-Breschkin et al.   ANTIVIRAL RESEARCH

Dynamic Variation and Reversion in the Signature Amino Acids of H7N9 Virus During Human Infection

(2018) Xiaohui Zou et al.   JOURNAL OF INFECTIOUS DISEASES

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

(2018) A Danielle Iuliano et al.   LANCET

Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection

(2018) Pierre Roques et al.   Viruses-Basel

The mechanism of resistance to favipiravir in influenza

(2018) Daniel H. Goldhill et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reconciling estimates of the global influenza burden

(2018) Sheena G Sullivan et al.   Lancet Respiratory Medicine

Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017

(2018) Christopher E Troeger et al.   Lancet Respiratory Medicine

Novel influenza A viruses and pandemic threats

(2017) Timothy M Uyeki et al.   LANCET

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

(2017) Yousuke FURUTA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study

(2017) John H Beigel et al.   Lancet Respiratory Medicine

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

(2016) Vincent Madelain et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses

(2016) Jennifer L. McKimm-Breschkin et al.   ANTIVIRAL RESEARCH

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

(2016) Vincent Madelain et al.   CLINICAL PHARMACOKINETICS

How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections?

(2016) Carolin Vegvari et al.   PLoS One

Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever

(2015) Brian B. Gowen et al.   ANTIVIRAL RESEARCH

Treating Influenza With Neuraminidase Inhibitors

(2015) Janice K. Louie et al.   JAMA Internal Medicine

Antiviral Susceptibility of Variant Influenza A(H3N2)v Viruses Isolated in the United States from 2011 to 2013

(2014) K. Sleeman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multisystem failure: the story of anti-influenza drugs

(2014) T. Jefferson et al.   BMJ-British Medical Journal

Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase

(2013) Hidehiro Sangawa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

(2013) Yousuke Furuta et al.   ANTIVIRAL RESEARCH

Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age

(2013) James E. Fielding et al.   Influenza and Other Respiratory Viruses

T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro

(2013) T. Baranovich et al.   JOURNAL OF VIROLOGY

Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance

(2013) Yunwen Hu et al.   LANCET

Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives

(2011) Aeron C Hurt et al.   LANCET INFECTIOUS DISEASES

Rapid Detection of Influenza A Pandemic (H1N1) 2009 Virus Neuraminidase Resistance Mutation H275Y by Real-Time Reverse Transcriptase PCR

(2010) M. Hindiyeh et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States

(2009) Nila J. Dharan   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses

(2009) M. Kiso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA